<DOC>
	<DOCNO>NCT01409694</DOCNO>
	<brief_summary>The purpose study compare effect 24 week oral intake vitamin D3 ( cholecalciferol ) effect placebo change cognitive performance patient suffer moderate Alzheimer 's disease relate disorder ( ADRD ) receive memantine .</brief_summary>
	<brief_title>Alzheimer 's Disease - Input Vitamin D With mEmantine Assay</brief_title>
	<detailed_description>Current treatment Alzheimer 's disease relate disorder ( ADRD ) symptomatic temporarily slow ADRD . Future possibilities care could rely multi-target drug therapy address simultaneously several pathophysiological process lead neurodegeneration . We hypothesize combination memantine vitamin D could neuroprotective ADRD , thereby limit neuronal loss cognitive decline . The primary objective trial compare effect 24 week oral intake vitamin D3 effect placebo evolution cognitive performance patient suffer moderate ADRD receive memantine . The secondary objective study follow : - To compare effect 12 week oral intake vitamin D3 effect placebo evolution cognitive performance patient suffer moderate ADRD receive memantine . - To compare effect 12 24 week oral intake vitamin D3 effect placebo evolution functional ability patient suffer moderate ADRD receive memantine . - To compare effect 12 24 week oral intake vitamin D3 effect placebo evolution postural gait performance patient suffer moderate ADRD receive memantine . - To determine compliance treatment tolerance oral intake vitamin D3 patient suffer moderate ADRD receive memantine .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Age ≥ 60 year Diagnosis moderate Alzheimer 's disease relate disorder ( DSMIV/NINCDSADRDA ) score MiniMental State Examination ( MMSE ) 10 20 inclusively To hypovitaminosis D ( i.e. , serum 25hydroxyvitamin D [ 25OHD ] concentration &lt; 30 ng/mL ) To hypercalcemia ( define serum calcium concentration ≥ 2,65 mmol/L ) To give sign informed consent form participate trial ( informed consent form obtain trust person legal representative , appropriate ) To affiliate French Social Security The use standard antidementia drug ( i.e. , anticholinesterasics , memantine , vasodilatators ) past 60 day Severe hepatic renal failure Severe , unstable poorly control medical condition time inclusion Other cognitive disorder ( untreated dysthyroid , deficiency vitamin B9 B12 , chronic ongoing ethylism , history syphilis , stroke , delirium reveal Confusion Assessment Method ( CAM ) , severe depressive symptomatology ( Geriatric Depression score ≥ 10/15 ) ) Contraindications memantine vitamin D Enrollment another simultaneous clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Alzheimer Disease</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Cholecalciferol</keyword>
	<keyword>Memantine</keyword>
	<keyword>Cognition Disorders</keyword>
</DOC>